• About us
• Contact

Advertisement

Organisation › Details

Annexon Biosciences Inc.

Annexon Biosciences is creating and developing proprietary therapeutic products that modulate the classical complement pathway. Our pipeline is based on breakthrough research showing that the initiating molecule of the classical pathway, C1q, stimulates an immune-mediated attack that causes cell loss and tissue damage in a broad array of autoimmune, neurodegenerative and ophthalmic disorders. *

 

	Start	2011-01-01 established
	End	2020-07-01 renamed before?
	Group	Annexon Inc. (ANNX)
	Industry	BIOTECH
	Person	Love, Douglas (Doug) (Annexon Biosciences 201812 CEO)
	Region	South San Francisco, CA
	Country	United States (USA)
	Street	180 Kimball Way 2nd Floor, Suite 200
	City	94080 South San Francisco, CA
	Tel	+1-650-822-5500
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: Annexon Biosciences Inc.. (12/19/18). "Press Release: Annexon Biosciences Closes $75 Million Financing". South San Francisco, CA.
		Record changed: 2023-07-10

Advertisement

More documents for Annexon Inc. (ANNX)

• [1] Annexon, Inc.. (7/1/20). "Press Release: Annexon Closes $100 Million Financing to Advance Broad Pipeline of Classical Complement Therapeutics". South San Francisco, CA....
• [2] Annexon Biosciences Inc.. (12/19/18). "Press Release: Annexon Biosciences Closes $75 Million Financing". South San Francisco, CA....
• [3] Annexon Biosciences. (3/9/17). "Press Release: Annexon Biosciences Appoints Bill Young as Chairman and Adds Tom Wiggans to Board of Directors". South San Francisco, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.